Partnerships

Our Partners and Collaborators

Avicenna Oncology

Avicenna Oncology

We are collaborating with Avicenna Oncology GmbH, a leading antibody drug conjugate development company based in Basel, Switzerland, to focus on the development of new PDCs by combining our patented phospholipid ether delivery platform with Avicenna's novel cytotoxic warheads (potent anti-cancer small molecules). Those novel cytotoxic warheads were previously attempted to be made as antibody drug conjugates and were unsuccessful.

MORE ABOUT OUR PARTNERSHIP WITH AVICENNA ONCOLOGY
Orano Med

Orano Med

Orano Med (formerly AREVA Med) is a nuclear medicine biotech company developing innovative therapies in oncology. Orano Med has developed new processes for producing lead-212 (212Pb), a rare radioactive isotope used in Targeted Alpha Therapy (TAT), an innovative and promising approach in nuclear medicine of utilizing a shorter energy range of the alpha particle to destroy cancer cells while limiting the impact on nearby healthy cells. Orano Med has been pursuing partnerships that allow the development of 212Pb as an effective therapy. Orano Med is a subsidiary of Orano.

More About Our Partnership with Orano Med
IntoCell

IntoCell

IntoCell is a Korea-based biotechnology company dedicated to the development and commercialization of novel antibody drug conjugate (ADC) platform technologies comprising scaffold moiety, ligands, toxins, linkers and conjugation methods. IntoCell has developed a novel self-immolative Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) linker that works with a wide variety of functional groups, triggering groups, and both phenolic and non-phenolic payloads. The resulting ADCs have proven to be highly stable in chemical and biological environments and have demonstrated excellent potencies in-vitro and in-vivo. IntoCell has also developed proprietary benzodiazepine dimers and modified duocarmycinoids that show high potency with improved safety in preclinical models. IntoCell has created an OHPAS Linker-toxin Library containing a variety of toxins that can be optimized for the fast delivery of a preclinical candidate in novel ADC programs. Using its novel chemistries, IntoCell is developing a pipeline of proprietary ADCs that includes a B7-H3 program which is demonstrating excellent preclinical data.

More About Our Partnership with IntoCell
LegoChemBio

LegoChemBio

LegoChem Biosciences is a biopharmaceutical company focusing on the development of next-generation novel therapeutics utilizing its proprietary medicinal drug discovery technology LegoChemistry & ADC platform technology ConjuAll. Since its foundation in 2006, LCB has focused on the research and development of ADC (Antibody-Drug-Conjugates), antibiotics, anti-fibrosis and anticancer therapeutics based on proprietary platform technologies.

More About Our Partnership with LegoChemBio

Collaborate With Us!

Contact Us